TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12810936

Group type: EXPERIMENTAL
Intervention: Minimal intervention by occupational specialists involving information about the disorder, encouragement to stay active, and instruction in graded self‐performed exercises.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Minimal intervention by occupational specialists
Number of subjects: 266

Group type: COMPARATOR
Intervention: Not applicable (usual approach in general practice)
Number of subjects: 266
Study: 15505965

Group type: EXPERIMENTAL
Intervention: Dual-route model treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Single-route model treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control treatments
Number of subjects: 44
Study: 9176041

Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 25
Study: 1585899

Group type: COMPARATOR
Intervention: Placebo recipients (20,744)
Number of subjects: 32642
Study: 3982903

Group type: EXPERIMENTAL
Intervention: Doxapram therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aminophylline therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aminophylline plus doxapram therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aminophylline plus placebo
Number of subjects: 26
Study: 28902114

Group type: EXPERIMENTAL
Intervention: Soccer plus RS-COD training program
Number of subjects: 29

Group type: COMPARATOR
Intervention: Soccer-only group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: RS-COD training
Number of subjects: 29
Study: 29140864

Group type: EXPERIMENTAL
Intervention: 2.5 mL 0.5% bupivacaine with 1:200,000 epinephrine (Group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 2.5 mL of 1% lidocaine with 1:100,000 epinephrine (Group B)
Number of subjects: 51
Study: 26581198

Group type: EXPERIMENTAL
Intervention: Introductory presentation plus workshop
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Dissemination by student representatives/peers
Number of subjects: 395

Group type: COMPARATOR
Intervention: Advertisement materials only
Number of subjects: 395
Study: 24946636

Group type: EXPERIMENTAL
Intervention: Embedding therapy on back‐shu points and front‐mu points and needle‐pricking therapy on Sifeng (EX‐UE 10)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Metformin hydrochloride tablet (0.5 g, once a day for the first week, twice a day from the second week)
Number of subjects: 85
Study: 22325731

Group type: EXPERIMENTAL
Intervention: Handrubbing with alcohol covering all hand surfaces
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Handrubbing with alcohol using the standard 7-step technique
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Handwashing with chlorhexidine using the standard 7-step technique
Number of subjects: 120
Study: 19650983

Group type: EXPERIMENTAL
Intervention: Lactose-free formula feeding
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional formula feeding
Number of subjects: 120
Study: 17500623

Group type: EXPERIMENTAL
Intervention: Bupropion SR treatment
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Presence of DRD2 A1 allele and SLC6A3 status
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Absence of DRD2 A1 allele and SLC6A3 status
Number of subjects: 323
Study: 14697476

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 847

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study: 12114418

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg/day given p.o.)
Number of subjects: 261
Study: 9686713

Group type: EXPERIMENTAL
Intervention: Generic postcard
Number of subjects: 24743

Group type: EXPERIMENTAL
Intervention: Personalized postcard from their physician
Number of subjects: 24743

Group type: EXPERIMENTAL
Intervention: Personalized letter from their physician, tailored to their health risk
Number of subjects: 24743

Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 24743
Study: 8026259

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg on weekends (group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every other day (group C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All three dose regimens of omeprazole
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily (group A), Omeprazole 40 mg on weekends (group B), Omeprazole 20 mg every other day (group C)
Number of subjects: 45
Study: 2918132

Group type: COMPARATOR
Intervention: Placebo varnish (group I)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fluoride varnish (group II)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (group III)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fluoride-plus-chlorhexidine varnish (group IV)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (second treatment)
Number of subjects: 26
Study: 30979589

Group type: EXPERIMENTAL
Intervention: CP-CET (cetuximab plus carboplatin and paclitaxel)
Number of subjects: 108

Group type: COMPARATOR
Intervention: CP (carboplatin and paclitaxel)
Number of subjects: 108
Study: 28328795

Group type: COMPARATOR
Intervention: HBsAg positivity in Zimbabwe (12.2%) vs. Uganda (7.7%)
Number of subjects: 3316

Group type: COMPARATOR
Intervention: HBeAg detection among HBsAg-positive patients (37%)
Number of subjects: 3316

Group type: COMPARATOR
Intervention: HBV DNA status in HBsAg-positive patients
Number of subjects: 3316

Group type: COMPARATOR
Intervention: Detectable HBV DNA in HBeAg-positive (96%) vs. HBeAg-negative (70%) patients
Number of subjects: 3316
Study: 26817306

Group type: EXPERIMENTAL
Intervention: Oral sertraline hydrochloride at 50 mg qd for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Four-spot caressing for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of oral sertraline hydrochloride and four-spot caressing for 12 weeks
Number of subjects: 90
Study: 23229158

Group type: EXPERIMENTAL
Intervention: 6-month print-based theory tailored physical activity intervention (n = 224)
Number of subjects: 448

Group type: COMPARATOR
Intervention: 6-month health/wellness contact control arm (n = 224)
Number of subjects: 448
Study: 21626284

Group type: EXPERIMENTAL
Intervention: Desmopressin 125 ng
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Desmopressin 250 ng
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Desmopressin 500 ng
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Desmopressin 250 ng and 500 ng
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Desmopressin 500 ng i.v.
Number of subjects: 13
Study: 17347165

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 78

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 78
Study: 15132126

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (single dose)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12581546

Group type: EXPERIMENTAL
Intervention: Formoterol (12 and 24 microg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Albuterol (180 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9789694

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) administered intracoronarily at a dosage of 25 ng/kg/min for 8 min during the second balloon inflation.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) administered intracoronarily.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline infusion (control group).
Number of subjects: 15
Study: 8728803

Group type: EXPERIMENTAL
Intervention: Intracoronary isosorbide mononitrate (ISMN) 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2676063

Group type: EXPERIMENTAL
Intervention: Low-field (0.08 T) magnetic resonance (MR) imaging
Number of subjects: 124
Study: 145654

Group type: EXPERIMENTAL
Intervention: Aerosolized fenoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerosolized salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerosolized ipratropium bromide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerosolized terbutaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Administration by investigator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-administration by patients
Number of subjects: 0
Study: 30995611

Group type: EXPERIMENTAL
Intervention: Full dose IR images
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Half and quarter doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Filtered back projection (FBP) and iterative reconstruction (IR) algorithms
Number of subjects: 10
Study: 28399633

Group type: EXPERIMENTAL
Intervention: Tourniquet not inflated
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tourniquet inflated
Number of subjects: 50
Study: 26151886

Group type: EXPERIMENTAL
Intervention: Rivaroxaban intake at 08:00 h
Number of subjects: 16

Group type: COMPARATOR
Intervention: No rivaroxaban intake
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rivaroxaban intake at 20:00 h
Number of subjects: 16
Study: 23391126

Group type: EXPERIMENTAL
Intervention: Interactive voice response (IVR) outreach
Number of subjects: 24167

Group type: COMPARATOR
Intervention: Control (mailed outreach or natural levels of inbound calling)
Number of subjects: 24167
Study: 21699587

Group type: EXPERIMENTAL
Intervention: 400 mL of oral supplement and dietary advice
Number of subjects: 125

Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Buzby definition for surgical site infections in weight-losing patients
Number of subjects: 125
Study: 18408265

Group type: EXPERIMENTAL
Intervention: Oil pulling with sesame oil for 10 min every day before brushing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash for 10 min every day before brushing
Number of subjects: 20
Study: 17227607

Group type: EXPERIMENTAL
Intervention: Coaching protocol, online tutorial, skills building workshop and performance feedback
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual practices (Control)
Number of subjects: 41
Study: 15013471

Group type: EXPERIMENTAL
Intervention: Thyroid hormone supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no thyroid hormone supplementation)
Number of subjects: 0
Study: 12199262

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral morphine tablets
Number of subjects: 0
Study: 9718255

Group type: EXPERIMENTAL
Intervention: Humorous film
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Longer film (regardless of type)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Holocaust film
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Neutral film
Number of subjects: 200

Group type: COMPARATOR
Intervention: No-film group
Number of subjects: 200
Study: 8110568

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 40 ml with morphine 5 mg (group BM5)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 40 ml with morphine 2 mg (group BM2)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 40 ml only (group B0)
Number of subjects: 58
Study: 2761061

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (1.2 g)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 38
Study: 779054

Group type: EXPERIMENTAL
Intervention: Indoramin (mean dose: 158 ± 9 mg per day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Methyldopa (mean dose: 1540 ± 90 mg per day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 31
Study: 31160472

Group type: EXPERIMENTAL
Intervention: VR interactive game
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard of care (topical numbing cream, positioning, distraction by a specialized pain nurse)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 64
Study: 28385431

Group type: EXPERIMENTAL
Intervention: Light-polymerizing cement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dual-polymerizing cement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both light- and dual-polymerizing modes
Number of subjects: 10
Study: 25908703

Group type: EXPERIMENTAL
Intervention: CPMHA (Belotero Balance)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPMHA with lidocaine (BEL‐L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPMHA with lidocaine and epinephrine (BEL‐LE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control: CPMHA (Belotero Balance)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control: CPMHA with lidocaine (BEL‐L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control: CPMHA with lidocaine and epinephrine (BEL‐LE)
Number of subjects: 30
Study: 23521871

Group type: EXPERIMENTAL
Intervention: Adjunctive quetiapine (QTP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 55
Study: 21226678

Group type: EXPERIMENTAL
Intervention: Zolpidem (5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sleep inertia (placebo)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wakefulness control (placebo)
Number of subjects: 25
Study: 20178218

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide bleaching agent (Pola Night) for 2 hours a day for 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no bleaching treatment)
Number of subjects: 20
Study: 17976099

Group type: EXPERIMENTAL
Intervention: CRT group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15379110

Group type: EXPERIMENTAL
Intervention: Home hospitalization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient care in a general hospital ward
Number of subjects: 0
Study: 11689755

Group type: EXPERIMENTAL
Intervention: 2% clindamycin phosphate vaginal cream
Number of subjects: 79

Group type: COMPARATOR
Intervention: Triple sulfonamide vaginal cream
Number of subjects: 79
Study: 9387133

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) given intravenously for 8 weeks at 50 Ul/kg body weight three times a week, then subcutaneously for 4 weeks at 25 Ul/kg body weight twice a week, and for the last 8 weeks at 25 Ul/kg body weight once a week.
Number of subjects: 25
Study: 7696452

Group type: EXPERIMENTAL
Intervention: Budesonide retention enema (2.3 mg/115 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prednisolone disodium phosphate enema (31.25 mg/125 mL)
Number of subjects: 100
Study: 2902920

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30043086

Group type: EXPERIMENTAL
Intervention: Swan neck coiled tip catheter
Number of subjects: 46

Group type: COMPARATOR
Intervention: Swan neck straight tip catheter
Number of subjects: 46
Study: 30097333

Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 27263164

Group type: EXPERIMENTAL
Intervention: Asfora Bullet Cage System (ABCS)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Medtronic‐Sofamor Danek Inter Fix Threaded Fusion Device (MSDIFD)
Number of subjects: 257
Study: 24368344

Group type: EXPERIMENTAL
Intervention: Pneumonia hospitalization
Number of subjects: 3069

Group type: EXPERIMENTAL
Intervention: Other infections hospitalization
Number of subjects: 3069
Study: 22767144

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² plus Irinotecan 250 mg/m² (Day 1)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Docetaxel 85 mg/m² (Day 1) followed by 5-fluorouracil 750 mg/m² per day (Days 1-5)
Number of subjects: 85
Study: 20646829

Group type: EXPERIMENTAL
Intervention: Antisiphon group (Vygon shunt)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-antisiphon group (Chhabra shunt and Ceredrain)
Number of subjects: 40
Study: 17195712

Group type: EXPERIMENTAL
Intervention: Pertussis immune globulin (P‐IGIV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 15947625

Group type: EXPERIMENTAL
Intervention: 3-month liquid diet weight reduction program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 48
Study: 12133144

Group type: EXPERIMENTAL
Intervention: Online lecture on screening
Number of subjects: 95

Group type: COMPARATOR
Intervention: Live lecture on screening
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Online lecture with audio feed
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Online lecture without audio feed
Number of subjects: 95
Study: 9472866

Group type: EXPERIMENTAL
Intervention: Pima Action
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Pima Pride
Number of subjects: 95

Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 95
Study: 8729757

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no treatment for 6 months)
Number of subjects: 50
Study: 2640224

Group type: EXPERIMENTAL
Intervention: Focal and scattered photocoagulation applied over the affected area
Number of subjects: 20

Group type: COMPARATOR
Intervention: Photocoagulation to reduce blood flow of the afferent arteriole
Number of subjects: 20
Study: 894973

Group type: EXPERIMENTAL
Intervention: Modified pilocarpine solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pure pilocarpine solution
Number of subjects: 30
Study: 31515141

Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Al with GLA-AF (30µg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Al with GLA-AF (100µg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Al without GLA-AF (10µg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Al without GLA-AF (30µg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Al with GLA-AF (10µg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 72
Study: 28461286

Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Pure e-learning
Number of subjects: 1237
Study: 25371042

Group type: EXPERIMENTAL
Intervention: Exercise (EX) - 60 minutes of running including eight 3-minute intervals at 90% VO2max before diving
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON) - No exercise before diving
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (EX and CON)
Number of subjects: 16
Study: 24311384

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 529
Study: 21946291

Group type: EXPERIMENTAL
Intervention: Stay In Balance program (SIB)
Number of subjects: 135
Study: 19228681

Group type: EXPERIMENTAL
Intervention: Targeted invitation to non-attenders combined with GP visits for quality enhancements
Number of subjects: 117129
Study: 17181400

Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) intervention including a daily jumping program (Bounce at the Bell) plus 15 minutes/day of classroom physical activity.
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control group (CON) of same-sex controls not participating in AS! BC.
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) intervention.
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control group (CON).
Number of subjects: 410
Study: 15667046

Group type: EXPERIMENTAL
Intervention: VR group (neurofeedback with virtual reality)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Non-VR group (neurofeedback without virtual reality)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 16372152

Group type: EXPERIMENTAL
Intervention: Relative risk reduction
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tumor response rate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Median overall survival
Number of subjects: 102

Group type: COMPARATOR
Intervention: Observation/supportive care
Number of subjects: 102

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 102

Group type: COMPARATOR
Intervention: Surgery plus chemotherapy
Number of subjects: 102
Study: 10547913

Group type: EXPERIMENTAL
Intervention: Personal appointments (intervention group)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 640
Study: 8893571

Group type: EXPERIMENTAL
Intervention: Preoperative platelet-rich plasma (PRP) harvest
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (without PRP harvest)
Number of subjects: 40
Study: 1830250

Group type: EXPERIMENTAL
Intervention: Weight-reduction program of diet, exercise, and behavior modification plus combination anorectic drug therapy (fenfluramine and phentermine)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 6294517

Group type: COMPARATOR
Intervention: ACTH
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dose intravenous cyclophosphamide plus ACTH
Number of subjects: 58

Group type: COMPARATOR
Intervention: Plasma exchange, low-dose oral cyclophosphamide, and ACTH
Number of subjects: 58
Study: 31496674

Group type: EXPERIMENTAL
Intervention: Indacaterol (IND) 150 μg q.d.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tiotropium (TIO) 18 μg q.d.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both IND and TIO
Number of subjects: 42
Study: 29945934

Group type: EXPERIMENTAL
Intervention: Newer-generation ultrathin strut drug-eluting stents (strut thickness <70 µm)
Number of subjects: 11658

Group type: COMPARATOR
Intervention: Thicker strut second-generation drug-eluting stents
Number of subjects: 11658
Study: 28039287

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling intervention for 6 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids in plasma
Number of subjects: 25
Study: 24809976

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation with VT 6 ml/kg predicted body weight
Number of subjects: 28

Group type: COMPARATOR
Intervention: Volume-controlled ventilation with VT 10 ml/kg predicted body weight
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both VT groups
Number of subjects: 28